MENOTAS HP 150

Menotas HP 150IU Injection contains the active substance Menotrophin. It is an ovulation stimulator that belongs to the group of medications called gonadotropins. It is a highly purified mixture of follicle-stimulating hormone (FSH) and luteinising hormone (LH). They are natural hormones produced in both males and females. They help the reproductive organs to work normally.

Menotas HP 150IU Injection is used to treat infertility in women who are not ovulating, including those with polycystic ovarian disease, and who have not responded to treatment with another medicine called clomiphene citrate. It is also used to help multiple follicles and, therefore, to promote fertility in women undergoing IVF (in-vitro fertilisation)  or other types of assisted conception. It is also indicated to treat infertility in men due to low sperm count.

Do not take Menotas HP 150IU Injection if you are allergic to menotrophin or any of the other ingredients of this medicine. Do not take this medicine if you have a tumour in the pituitary gland  (a gland located on the base of the brain which produces certain hormones, including growth hormones)  or in the hypothalamus (an area located under the part of the brain called the thalamus which controls the conditions within your body including body temperature and blood pressure) or in the uterus, ovaries, breast, testicles, or in the prostate gland. Before initiating the treatment, you will be checked for underactive thyroid problems, hormone levels, and tumours of the pituitary and hypothalamus.

Do not take this medicine if you have ovarian cysts that are not due to PCOD, vaginal bleeding, early menopause, physical problems in the reproductive organs if your womb has been removed, and if you are pregnant or breastfeeding. Inform your physician immediately if you face any of these symptoms, such as abdominal pain and swelling, weight gain, diarrhoea, difficulty in breathing, and decreased urination. Inform your physician if you have or have had a liver problem or a history of blood clotting disease before starting the treatment.